DFX Intelligence
Antares Therapeutics, Inc.
Venture-backed company · Stage unknown· Boston, MA
As of · the latest observation of this company; each round carries its own date
Form D industry: Biotechnology
As of · the latest observation of this company; each round carries its own date
4 additional officers and directors
Every relationship, signal and contact on this record, with the source on each.
Includes 3 days of DFX Intelligence. Then $199/month unless canceled.
What matters now
- 5 directorsboard
5 directors on record from Form D filings and board-seat attributions.
The board is who decides on the next round and on a sale.
Drawing the relationship network…
Facts
Financing history
2 rounds
- May 1, 2025Form D equity offering · $30.0M (form d sold) · 35 investorsFact Form D · “Antares Therapeutics, Inc. filed Form D: $30,000,000 sold of $136,650,000, Biotechnology”
- Mar 5, 2025Form D equity offering · $40.0M (form d sold) · 3 investorsFact Form D · “Antares Therapeutics, Inc. filed Form D: $40,000,000 sold of $40,000,000, Biotechnology”
Investors on record
0 edges
No named investor yet.
Ownership and outcomes
How these are wordedA company a buyout or growth firm lists on its own site is “listed in the portfolio of”, never “acquired by”. A date prints only when a deal record gives one; otherwise the row says when DFX first saw it.none on record
Outcome stated by investors
No firm portfolio page lists this company, so no outcome is stated.
No later owner or exit on record: no private equity sponsor position and no acquisition, listing or IPO report names this company.
Credit relationships
How a loan is matchedA BDC reports its loans by borrower name. A position shows here only when the match passed a precision gate (a hand-labelled sample was 29 of 30 correct); the tier and confidence are printed on each row. Amounts are the lender’s reported position, never a round.none on record
No lender position matched to this company.
People
5 officers, 5 directors
- Adam Friedman Executive Officer/Director sec.gov
- Andrew Fedder Executive Officer sec.gov
- Andrew Fedder Executive Officer/Director sec.gov
- Menelas N. Pangalos Director Fact
- Jeffrey Albers Director Fact
Show all 6 officers and directors
- Adam Friedman Executive Officer/Director sec.gov
- Andrew Fedder Executive Officer sec.gov
- Andrew Fedder Executive Officer/Director sec.gov
- Menelas N. Pangalos Director Fact
- Jeffrey Albers Director Fact
- Keith Flaherty Director Fact
Timeline
5 events
- May 15, 2025Antares Therapeutics, Inc. filed Form D: $30,000,000 sold of $136,650,000, BiotechnologyForm D filed Fact Form D
- Mar 12, 2025Andrew Fedder is an executive officer of Antares Therapeutics, Inc. (first Form D 2025-03-12), and was an executive officer of Scorpion Therapeutics, Inc. (first Form D 2020-05-19)Repeat founder Inference
- Mar 12, 2025Adam Friedman is an executive officer of Antares Therapeutics, Inc. (first Form D 2025-03-12), and was an executive officer of Scorpion Therapeutics, Inc. (first Form D 2020-05-19)Repeat founder Inference
- Mar 12, 2025Brian Piper is an executive officer of Antares Therapeutics, Inc. (first Form D 2025-03-12), and was an executive officer of Scorpion Therapeutics, Inc. (first Form D 2020-05-19)Repeat founder Inference
- Mar 12, 2025Antares Therapeutics, Inc. filed Form D: $40,000,000 sold of $40,000,000, BiotechnologyForm D filed Fact Form D
Evidence
30 observations
Every observation on this company
- Entity type: Corporation May 15, 2025 Fact Form D
- Entity type: Corporation Mar 12, 2025 Fact Form D
- Form D industry group: Biotechnology May 15, 2025 Fact Form D
- Form D industry group: Biotechnology Mar 12, 2025 Fact Form D
- Amendment: false May 15, 2025 Fact Form D
- Amendment: false Mar 12, 2025 Fact Form D
- Revenue range (Form D): Decline to Disclose May 15, 2025 Fact Form D
- Revenue range (Form D): Decline to Disclose Mar 12, 2025 Fact Form D
- Incorporated: withinFiveYears May 15, 2025 Fact Form D
- Incorporated: withinFiveYears Mar 12, 2025 Fact Form D
- Jurisdiction: Delaware May 15, 2025 Fact Form D
- Jurisdiction: Delaware Mar 12, 2025 Fact Form D
- Amount sold (Form D): $30.0M May 15, 2025 Fact Form D
- Amount sold (Form D): $40.0M Mar 12, 2025 Fact Form D
- Offering amount (Form D): $137M May 15, 2025 Fact Form D
- Offering amount (Form D): $40.0M Mar 12, 2025 Fact Form D
- Exemptions: 06b May 15, 2025 Fact Form D
- Exemptions: 06b Mar 12, 2025 Fact Form D
- First sale: 2025-05-01 May 15, 2025 Fact Form D
- First sale: 2025-03-05 Mar 12, 2025 Fact Form D
- Investors (Form D): 35 May 15, 2025 Fact Form D
- Investors (Form D): 3 Mar 12, 2025 Fact Form D
- Minimum investment (Form D): 0 May 15, 2025 Fact Form D
- Minimum investment (Form D): 0 Mar 12, 2025 Fact Form D
- Securities offered: equity May 15, 2025 Fact Form D
- Securities offered: Debt, option Mar 12, 2025 Fact Form D
- Office address: May 15, 2025 Fact Form D
- Office address: Mar 12, 2025 Fact Form D
- Year of incorporation: 2025 May 15, 2025 Fact Form D
- Year of incorporation: 2025 Mar 12, 2025 Fact Form D
Record history
2 dated events on the change ledger, latest event first
- Form D filed2025-05-15source on record
- Form D filed2025-03-12source on record
The ledger records every merge, rename and reclassification this record went through and the dated filings observed on it, so the identity on this page can be traced to the records it was built from. The ledger's own sentences name other records, so they show with the names.